<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854397</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.180</org_study_id>
    <nct_id>NCT02854397</nct_id>
  </id_info>
  <brief_title>Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population</brief_title>
  <acronym>BRADYKID</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In emergency room, this is crucial to diagnose an acute attack of hereditary angioedema (HAE)
      to quickly provide the efficient treatment. Currently, there is no specific biomarker for
      acute attack of bradykinin-mediated angioedema to help clinicians for patient care. However,
      previous works are carried out for that purpose. All the potential candidate biomarkers must
      be validated in prospective studies to estimate their specificity and sensitivity values, and
      to understand their potential utility in patient care.

      The main goal of this clinical trial is to estimate the diagnostic value of VE-cadherin in
      pediatric population, for the differential diagnosis between HAE crisis and angioedema
      resulting of mast cell activation crisis (the main differential diagnosis of HAE).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VE-cadherin level</measure>
    <time_frame>Half a day</time_frame>
    <description>For the diagnosis of acute attack of hereditary angioedema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosage of VE-cadherin (vascular endothelial)</measure>
    <time_frame>Half a day</time_frame>
    <description>Analysis of the cleaved fragments from high molecular weight kininogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of Fc KHPM</measure>
    <time_frame>Half a day</time_frame>
    <description>Analysis of the cleaved fragments from high molecular weight kininogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of D-dimer</measure>
    <time_frame>Half a day</time_frame>
    <description>Analysis of the cleaved fragments from high molecular weight kininogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of Tryptase</measure>
    <time_frame>Half a day</time_frame>
    <description>Analysis of the cleaved fragments from high molecular weight kininogen</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Hereditary Angioedema</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>patients with hereditary angioedema</arm_group_label>
    <description>A blood sample will be performed in crisis and 7 days after the crisis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with angioedema resulting of mast cell activation</arm_group_label>
    <description>A blood sample will be performed in crisis and 7 days after the crisis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy patients, without angioedema</arm_group_label>
    <description>A quantity of additional blood was taken from eligible patients who had a scheduled blood sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <arm_group_label>patients with hereditary angioedema</arm_group_label>
    <arm_group_label>patients with angioedema resulting of mast cell activation</arm_group_label>
    <arm_group_label>healthy patients, without angioedema</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with hereditary angioedema patients with angioedema resulting of mast cell
        activation healthy patients, without angioedema
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For HAE: patient with a documented diagnosis of HAE:

          -  type I (from an antigenic deficiency of the C1 esterase inhibitor) or type II (from a
             functional deficiency of the C1 esterase inhibitor). The existence of a mutation in
             SERPING1 was not necessary for the inclusion

          -  HAE with normal C1-INH (ex type III) with a required mutation in FXII gene or with a
             typical family history of HAE diagnosed by a specialized physician belonging to CREAK
             network.

        For AE resulting of mast cell activation: a documented diagnosis of AE resulting of mast
        cell activation included:

          -  mastocytosis,

          -  chronic spontaneous urticaria,

          -  acute urticaria after exposure of allergen during allergy challenge tests,

          -  mast cell activation syndrome.

        For the control group:

          -  composed of patients who presented a stabilized disease (that was not infectious, not
             auto-inflammatory or inflammatory disease and without implication of endothelial
             cells).

        Exclusion Criteria:

          -  Over 18 years or under 1 year.

          -  Diagnosis of HAE with a normal C1 esterase inhibitor or AE of unknown aetiology.

          -  Patients with HAE who received an acute attack treatment before the blood sample (the
             C1 esterase inhibitor concentrate or a bradykinin B2 receptor antagonist); patients
             with HAE who received a prophylactic treatment (danazol).

          -  Patients who were treated by omalizumab or corticosteroid treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Pagnier</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Pagnier, Md</last_name>
    <email>Apagnier@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Kevorkian-verguet</last_name>
    <email>ckevorkianverguet@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ludovic Martin</last_name>
      <phone>02 41 35 34 19</phone>
      <email>LuMartin@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabien Pelletier</last_name>
      <phone>03.81.21.87.13</phone>
      <email>fabien.pelletier@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Guez</last_name>
      <phone>05.56.79.56.79</phone>
      <email>stephane.guez@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hopital Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63503</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephane Echaubard</last_name>
      <phone>04 73 89 72 72</phone>
      <email>sechaubard@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Pagnier</last_name>
      <email>APagnier@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Kevorkian- Verguet</last_name>
      <email>ckevorkianverguet@chu-grenoble.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heloise Reumaux</last_name>
      <phone>03.20.44.46.62</phone>
      <email>heloisereumaux@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Freychet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Gayet</last_name>
      <phone>04 91 38 87 21</phone>
      <email>stephane.gayet@mail.ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélie Du Thanh</last_name>
      <phone>04.67.33.69.56</phone>
      <email>a-du-thanh@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irène Lemelle</last_name>
      <phone>03.83.15.47.34</phone>
      <email>i.lemelle@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ariane Zelinsky-Gurung</last_name>
      <phone>05.49.32.79.79</phone>
      <email>azelinsky@ch-niort.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>university hospital Saint-Antoine (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Fain</last_name>
      <phone>01 49 28 21 04</phone>
      <email>olivier.fain@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine Grall-Lerosey</last_name>
      <phone>02 32 88 82 16</phone>
      <email>martine.grall-lerosey@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Christine</last_name>
      <phone>05 34 55 85 95</phone>
      <email>pajot.c@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Boccon-Gibod I, Bouillet L. [Angioedema and urticaria]. Ann Dermatol Venereol. 2014 Nov;141 Suppl 3:S586-95. doi: 10.1016/S0151-9638(14)70162-0. Review. French.</citation>
    <PMID>25539680</PMID>
  </reference>
  <reference>
    <citation>Pagnier A. [Hereditary angioedema in childhood. Diagnosis and therapeutic challenges]. Presse Med. 2015 Jan;44(1):89-95. doi: 10.1016/j.lpm.2014.07.018. Epub 2014 Dec 12. Review. French.</citation>
    <PMID>25511651</PMID>
  </reference>
  <reference>
    <citation>Dinkel HP, Maroske J, Schrod L. Sonographic appearances of the abdominal manifestations of hereditary angioedema. Pediatr Radiol. 2001 Apr;31(4):296-8.</citation>
    <PMID>11321752</PMID>
  </reference>
  <reference>
    <citation>Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009 Nov;161(5):1153-8. doi: 10.1111/j.1365-2133.2009.09366.x. Epub 2009 Jun 22.</citation>
    <PMID>19709101</PMID>
  </reference>
  <reference>
    <citation>Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):18. doi: 10.1186/1710-1492-6-18.</citation>
    <PMID>20667121</PMID>
  </reference>
  <reference>
    <citation>El-Hachem C, Amiour M, Guillot M, Laurent J. [Hereditary angioneurotic edema: a case report in a 3-year-old child]. Arch Pediatr. 2005 Aug;12(8):1232-6. French.</citation>
    <PMID>15890504</PMID>
  </reference>
  <reference>
    <citation>Farkas H. Management of upper airway edema caused by hereditary angioedema. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):19. doi: 10.1186/1710-1492-6-19.</citation>
    <PMID>20667122</PMID>
  </reference>
  <reference>
    <citation>Sanchez A, Ecochard A, Maestracci M, Rodiere M. [Hereditary angioedema causing colocolic intussusception]. Arch Pediatr. 2008 Mar;15(3):271-4. doi: 10.1016/j.arcped.2007.12.004. Epub 2008 Mar 10. French.</citation>
    <PMID>18329867</PMID>
  </reference>
  <reference>
    <citation>Pritzker HA, Levin TL, Weinberg G. Recurrent colocolic intussusception in a child with hereditary angioneurotic edema: reduction by air enema. J Pediatr Surg. 2004 Jul;39(7):1144-6.</citation>
    <PMID>15213920</PMID>
  </reference>
  <reference>
    <citation>Parisi G, Chiarelli A, Squadrone NP, Galante E. Hereditary angioedema, a rare cause of recurrent abdominal pain. A report of 2 clinical cases and comments of a general nature Allergy Asthma Proc. 2013 Jul-Aug;34(4):312-27</citation>
  </reference>
  <reference>
    <citation>MacGinnitie AJ. Pediatric hereditary angioedema. Pediatr Allergy Immunol. 2014 Aug;25(5):420-7. doi: 10.1111/pai.12168. Epub 2013 Dec 9. Review.</citation>
    <PMID>24313851</PMID>
  </reference>
  <reference>
    <citation>Deroux A, Vilgrain I, Dumestre-Pérard C, Boccon-Gibod I, Bouillet L. Towards a specific marker for acute bradykinin-mediated angioedema attacks: a literature review. Eur J Dermatol. 2015 Jul-Aug;25(4):290-5. doi: 10.1684/ejd.2015.2547. Review.</citation>
    <PMID>25905454</PMID>
  </reference>
  <reference>
    <citation>Cugno M, Zanichelli A, Bellatorre AG, Griffini S, Cicardi M. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy. 2009 Feb;64(2):254-7. doi: 10.1111/j.1398-9995.2008.01859.x. Epub 2008 Dec 4.</citation>
    <PMID>19076541</PMID>
  </reference>
  <reference>
    <citation>Hogan AD, Schwartz LB. Markers of mast cell degranulation. Methods. 1997 Sep;13(1):43-52.</citation>
    <PMID>9281467</PMID>
  </reference>
  <reference>
    <citation>Brickman CM, Frank MM, Kaliner M. Urine-histamine levels in patients with hereditary angioedema (HAE). J Allergy Clin Immunol. 1988 Sep;82(3 Pt 1):403-6.</citation>
    <PMID>3170987</PMID>
  </reference>
  <reference>
    <citation>Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia. 2004 Jul;59(7):695-703. Review.</citation>
    <PMID>15200544</PMID>
  </reference>
  <reference>
    <citation>Kasperska-Zając A, Grzanka A, Czecior E, Misiolek M, Rogala B, Machura E. Acute phase inflammatory markers in patients with non-steroidal anti-inflammatory drugs (NSAIDs)-induced acute urticaria/angioedema and after aspirin challenge. J Eur Acad Dermatol Venereol. 2013 Aug;27(8):1048-52. doi: 10.1111/j.1468-3083.2012.04486.x. Epub 2012 Feb 21.</citation>
    <PMID>22348297</PMID>
  </reference>
  <reference>
    <citation>Fujii K, Konishi K, Kanno Y, Ohgou N. Acute urticaria with elevated circulating interleukin-6 is resistant to anti-histamine treatment. J Dermatol. 2001 May;28(5):248-50.</citation>
    <PMID>11436361</PMID>
  </reference>
  <reference>
    <citation>Kasperska-Zajac A, Brzoza Z. Increased D-dimer concentration in plasma of patients with severe acute urticaria. Br J Dermatol. 2009 Dec;161(6):1409-10. doi: 10.1111/j.1365-2133.2009.09466.x. Epub 2009 Sep 15.</citation>
    <PMID>19754863</PMID>
  </reference>
  <reference>
    <citation>Brevet: w/o 2008 062314 circulating ve-cadherin as a predictive marker of sensitivity or resistance to anti-tumoral treatment, and improved method for the detection of soluble proteins.</citation>
  </reference>
  <reference>
    <citation>Bouillet L, Sidibé A, Polena H, Mannic T, Deroux A, Stidder B, Vittecoq O, Vilgrain I. [Endothelial junctions: exploiting their instability in the development of biomarkers for vascular remodelling]. Med Sci (Paris). 2014 Jun-Jul;30(6-7):633-5. doi: 10.1051/medsci/20143006012. Epub 2014 Jul 11. French.</citation>
    <PMID>25014453</PMID>
  </reference>
  <reference>
    <citation>Bouillet L, Vilgrain I. VE-cadherin, a potential marker for endothelial cell activation during hereditary angioedema attacks. J Allergy Clin Immunol. 2014 Jul;134(1):241. doi: 10.1016/j.jaci.2014.04.016. Epub 2014 May 27.</citation>
    <PMID>24875615</PMID>
  </reference>
  <reference>
    <citation>Sidibé A, Polena H, Pernet-Gallay K, Razanajatovo J, Mannic T, Chaumontel N, Bama S, Maréchal I, Huber P, Gulino-Debrac D, Bouillet L, Vilgrain I. VE-cadherin Y685F knock-in mouse is sensitive to vascular permeability in recurrent angiogenic organs. Am J Physiol Heart Circ Physiol. 2014 Aug 1;307(3):H455-63. doi: 10.1152/ajpheart.00774.2013. Epub 2014 May 23.</citation>
    <PMID>24858856</PMID>
  </reference>
  <reference>
    <citation>Sidibé A, Polena H, Razanajatovo J, Mannic T, Chaumontel N, Bama S, Maréchal I, Huber P, Gulino-Debrac D, Bouillet L, Vilgrain I. Dynamic phosphorylation of VE-cadherin Y685 throughout mouse estrous cycle in ovary and uterus. Am J Physiol Heart Circ Physiol. 2014 Aug 1;307(3):H448-54. doi: 10.1152/ajpheart.00773.2013. Epub 2014 May 23.</citation>
    <PMID>24858855</PMID>
  </reference>
  <reference>
    <citation>Bouillet L, Mannic T, Arboleas M, Subileau M, Massot C, Drouet C, Huber P, Vilgrain I. Hereditary angioedema: key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation. J Allergy Clin Immunol. 2011 Jul;128(1):232-4. doi: 10.1016/j.jaci.2011.02.017. Epub 2011 Mar 24.</citation>
    <PMID>21439626</PMID>
  </reference>
  <reference>
    <citation>Suffritti C, Zanichelli A, Maggioni L, Bonanni E, Cugno M, Cicardi M. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency. Clin Exp Allergy. 2014 Dec;44(12):1503-14. doi: 10.1111/cea.12293.</citation>
    <PMID>24552232</PMID>
  </reference>
  <reference>
    <citation>Kahn R, Herwald H, Müller-Esterl W, Schmitt R, Sjögren AC, Truedsson L, Karpman D. Contact-system activation in children with vasculitis. Lancet. 2002 Aug 17;360(9332):535-41.</citation>
    <PMID>12241658</PMID>
  </reference>
  <reference>
    <citation>Ghannam A, Sellier P, Defendi F, Favier B, Charignon D, López-Lera A, López-Trascasa M, Ponard D, Drouet C. C1 inhibitor function using contact-phase proteases as target: evaluation of an innovative assay. Allergy. 2015 Sep;70(9):1103-11. doi: 10.1111/all.12657. Epub 2015 Jun 9.</citation>
    <PMID>26010015</PMID>
  </reference>
  <reference>
    <citation>Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009 Mar 26;113(13):2878-87. doi: 10.1182/blood-2008-06-165845. Epub 2008 Nov 13. Review.</citation>
    <PMID>19008457</PMID>
  </reference>
  <reference>
    <citation>Blohmé G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med Scand. 1972 Oct;192(4):293-8.</citation>
    <PMID>4562897</PMID>
  </reference>
  <reference>
    <citation>Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999 Jun;33(6):1431-5.</citation>
    <PMID>10373228</PMID>
  </reference>
  <reference>
    <citation>Cugno M, Hack CE, de Boer JP, Eerenberg AJ, Agostoni A, Cicardi M. Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med. 1993 Jan;121(1):38-43.</citation>
    <PMID>8426080</PMID>
  </reference>
  <reference>
    <citation>Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med. 1972 Apr 13;286(15):808-12.</citation>
    <PMID>4551861</PMID>
  </reference>
  <reference>
    <citation>Joseph K, Tholanikunnel BG, Wolf B, Bork K, Kaplan AP. Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. J Allergy Clin Immunol. 2016 Jun;137(6):1822-1829.e1. doi: 10.1016/j.jaci.2015.07.041. Epub 2015 Sep 26.</citation>
    <PMID>26395818</PMID>
  </reference>
  <reference>
    <citation>Kaplan AP, Austen KF. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med. 1971 Apr 1;133(4):696-712.</citation>
    <PMID>4251126</PMID>
  </reference>
  <reference>
    <citation>Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med. 1992 Jul;120(1):129-39.</citation>
    <PMID>1535355</PMID>
  </reference>
  <reference>
    <citation>Kluft C, Trumpi-Kalshoven MM, Jie AF, Veldhuyzen-Stolk EC. Factor XII-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator. Thromb Haemost. 1979 Jun 30;41(4):756-73.</citation>
    <PMID>483248</PMID>
  </reference>
  <reference>
    <citation>Nielsen EW, Johansen HT, Høgåsen K, Wuillemin W, Hack CE, Mollnes TE. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol. 1996 Aug;44(2):185-92.</citation>
    <PMID>8711433</PMID>
  </reference>
  <reference>
    <citation>Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy. 2015 May;70(5):506-13. doi: 10.1111/all.12587. Epub 2015 Feb 23.</citation>
    <PMID>25640891</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

